Clarity Pharmaceuticals Reports Fifth mCRPC Patient Achieving Undetectable Disease in SECuRE Trial
Event summary
- Clarity Pharmaceuticals reports a fifth patient with metastatic castration-resistant prostate cancer (mCRPC) achieving undetectable disease after two cycles of 67Cu-SAR-bisPSMA in the SECuRE trial Phase II.
- The patient, diagnosed 15 years ago, showed undetectable PSA after the first cycle and negative PSMA PET after the second cycle.
- All adverse events were mild (Grade 1), with no haematological or renal issues observed.
- The SECuRE trial Cohort Expansion Phase continues enrollment, with planned completion in 2026 and Phase III trial planning underway.
The big picture
Clarity Pharmaceuticals' SECuRE trial results reinforce the potential of its 67Cu-SAR-bisPSMA therapy in treating mCRPC, a market with significant unmet needs. The company's proprietary SAR technology and copper isotope pairing differentiate its approach, positioning it as a key player in the radiopharmaceutical space. The ongoing Phase II data, combined with three Fast Track Designations from the FDA, suggest a strategic advantage in accelerating regulatory approval and commercialization.
What we're watching
- Trial Momentum
- Whether the SECuRE trial can sustain its current pace of positive outcomes as enrollment continues.
- Regulatory Pathway
- The speed at which Clarity Pharmaceuticals advances toward a Phase III registrational trial and potential FDA approval.
- Commercialization Strategy
- How Clarity Pharmaceuticals positions its SAR-bisPSMA platform against existing and emerging radiopharmaceutical competitors.
Related topics